Suppr超能文献

盐皮质激素受体功能在治疗抵抗性抑郁症中的作用。

The role of mineralocorticoid receptor function in treatment-resistant depression.

机构信息

1King's College London, Institute of Psychiatry, Section of Neurobiology of Mood Disorders, London, UK.

出版信息

J Psychopharmacol. 2013 Dec;27(12):1169-79. doi: 10.1177/0269881113499205. Epub 2013 Jul 31.

Abstract

BACKGROUND

Treatment-resistant depression patients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis. However, few studies have examined the role of the mineralocorticoid receptor. This study aimed to evaluate the functional activity of the mineralocorticoid receptor system in regulating the hypothalamic-pituitary-adrenal axis in well-defined treatment-resistant depression patients.

MATERIAL AND METHOD

We recruited 24 subjects divided into: (a) treatment-resistant depression; (b) healthy controls. We evaluated: (a) the effect of combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone; (b) the effect of prednisolone with the mineralocorticoid receptor antagonist spironolactone; and (c) the effect of spironolactone alone. The response of the hypothalamic-pituitary-adrenal axis was measured using salivary cortisol and plasma levels of drugs were also measured.

RESULTS

Treatment-resistant depression patients had higher cortisol compared with controls after all challenges. In controls, spironolactone increased cortisol compared to placebo. The co-administration of spironolactone with prednisolone in controls decreases the suppressive effects of prednisolone. In contrast, in treatment-resistant depression, spironolactone did not increase cortisol compared to placebo and spironolactone with prednisolone had no effect on the suppressive effects of prednisolone. Patients with treatment-resistant depression had a reduction in the conversation of spironolactone to the active metabolite canrenone.

CONCLUSION

Our data confirmed that treatment-resistant depression is associated with hypercortisolism and these patients no longer show an hypothalamic-pituitary-adrenal response to the administration of a mineralocorticoid receptor antagonist, suggesting that there is a mineralocorticoid receptor malfunctioning, such as a down regulation, however, pharmacokinetics and pharmacodynamics in these subjects could also have had an effect on the lack of mineralocorticoid receptor response.

摘要

背景

治疗抵抗性抑郁症患者表现出糖皮质激素受体功能降低和下丘脑-垂体-肾上腺轴过度活跃。然而,很少有研究探讨矿物质皮质激素受体的作用。本研究旨在评估矿物质皮质激素受体系统在调节下丘脑-垂体-肾上腺轴中的功能活性,以明确治疗抵抗性抑郁症患者。

材料与方法

我们招募了 24 名受试者,分为:(a)治疗抵抗性抑郁症;(b)健康对照组。我们评估了:(a)联合使用皮质激素受体/矿物质皮质激素受体刺激物泼尼松龙的效果;(b)使用矿物质皮质激素受体拮抗剂螺内酯的效果;以及(c)单独使用螺内酯的效果。通过唾液皮质醇测量下丘脑-垂体-肾上腺轴的反应,同时也测量了药物的血浆水平。

结果

与对照组相比,治疗抵抗性抑郁症患者在所有挑战后皮质醇水平更高。在对照组中,螺内酯与安慰剂相比增加了皮质醇。在对照组中,螺内酯与泼尼松龙联合使用会降低泼尼松龙的抑制作用。相比之下,在治疗抵抗性抑郁症中,螺内酯与安慰剂相比并未增加皮质醇,且螺内酯与泼尼松龙联合使用对泼尼松龙的抑制作用没有影响。治疗抵抗性抑郁症患者螺内酯向活性代谢物坎利酮的转化减少。

结论

我们的数据证实,治疗抵抗性抑郁症与高皮质醇血症有关,这些患者对矿物质皮质激素受体拮抗剂的给药不再表现出下丘脑-垂体-肾上腺反应,表明存在矿物质皮质激素受体功能障碍,例如下调,但是,这些患者的药代动力学和药效学也可能对缺乏矿物质皮质激素受体反应产生影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验